HBM7004 moved closer to clinical development after Harbour BioMed received NMPA acceptance for its IND application. The company aims to advance treatment options for advanced solid tumors. Moreover, the milestone strengthens Harbour BioMed’s oncology research strategy. Harbour BioMed announced that China’s National Medical Products Administration accepted the Investigational New Drug application for HBM7004.
The company develops antibody therapeutics for oncology, immunology, and other disease areas. Furthermore, Harbour BioMed operates globally from Cambridge, Rotterdam, and Shanghai. HBM7004 is a B7H4xCD3 bispecific antibody developed through the company’s HBICE® platform. The therapy targets cancer through a differentiated immunotherapy approach. In addition, the program aims to improve both treatment efficacy and safety.
Preclinical Results Highlight HBM7004 Immunotherapy Potential
Preclinical studies showed that HBM7004 activated T cells in a B7H4-dependent manner within tumors. The therapy also demonstrated strong anti-tumor activity across several animal models.
The company also reported encouraging results when combining HBM7004 with a B7H4x4-1BB bispecific antibody. The combination produced a strong synergistic effect at a low effector-to-target cell ratio. As a result, the data suggested a promising therapeutic window.
“Following the recent FDA IND clearance for HBM7004, we are pleased that the NMPA has accepted the IND application for HBM7004 for the treatment of advanced solid tumors,” said Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed. “HBM7004 exemplifies our strategy of leveraging our proprietary technology platforms to develop differentiated next-generation immunotherapies that address significant unmet medical needs in oncology. Supported by encouraging preclinical data, we look forward to working closely with regulatory authorities and advancing this program toward clinical evaluation in China.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: PRNewswire.com
